Spyre Therapeutics, Inc. (SYRE): Cash & Equivalents
$85.72M
As of 2025-12-31
$162.01M
As of 2026-06-30
+35.0%
3-year compound annual growth
-1.0%
5-year compound annual growth
+11.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $85.72M | -4.1% | 2026-02-19, Balance as of period end |
| 2024-12-31 | $89.42M | -52.7% | 2026-02-19, Balance as of period end |
| 2023-12-31 | $188.89M | +441.8% | 2026-02-19, Balance as of period end |
| 2022-12-31 | $34.86M | +130.2% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $15.14M | -83.2% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $90.09M | +368.0% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $19.25M | -14.3% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $22.46M | +75.2% | 2020-02-24, Balance as of period end |
| 2017-12-31 | $12.82M | -73.2% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $47.75M | +63.0% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $29.29M | n/m | 2018-03-13, Balance as of period end |
| 2014-12-31 | $2.62M | n/a | 2017-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $85.72M | -4.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare SYRE, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗